Across TCGA pan-cancer cohorts, RAB3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB3A data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RAB3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB3A expression acts as an unfavorable survival marker.
SKCM, PRAD, and UCEC are the cancer types where RAB3A Mutation most reproducibly stratifies survival.